DE10109897A1
(en)
*
|
2001-02-21 |
2002-11-07 |
Novosom Ag |
Optional cationic liposomes and their use
|
DE10207177A1
(en)
*
|
2002-02-19 |
2003-09-04 |
Novosom Ag |
Optionally cationic lipids
|
US7858117B2
(en)
*
|
2002-02-21 |
2010-12-28 |
Novosom Ag |
Amphoteric liposomes and their use
|
AU2003266014B2
(en)
*
|
2002-05-06 |
2009-05-14 |
Alnylam Pharmaceuticals, Inc. |
Methods for delivery of nucleic acids
|
US7718189B2
(en)
|
2002-10-29 |
2010-05-18 |
Transave, Inc. |
Sustained release of antiinfectives
|
DE10255106A1
(en)
*
|
2002-11-24 |
2004-06-09 |
Novosom Ag |
Liposomal glucocorticoids
|
EP1547580A1
(en)
*
|
2003-12-23 |
2005-06-29 |
MediGene Oncology GmbH |
Loading of a camptothecin drug into colloidal nanoparticles
|
DE102004054730A1
(en)
|
2004-03-28 |
2006-05-11 |
Novosom Ag |
Serum stable amphoteric liposomes
|
US8815599B2
(en)
*
|
2004-06-01 |
2014-08-26 |
Pronai Therapeutics, Inc. |
Methods and compositions for the inhibition of gene expression
|
JP2008518998A
(en)
*
|
2004-11-05 |
2008-06-05 |
ノヴォソム アクチェンゲゼルシャフト |
Improvements in or relating to pharmaceutical compositions comprising oligonucleotides as active substances
|
EP1764090A1
(en)
*
|
2005-09-15 |
2007-03-21 |
Novosom AG |
Amphoteric liposomes for local drug applications
|
CA2587337A1
(en)
*
|
2004-11-19 |
2006-05-26 |
Novosom Ag |
Improvements in or relating to pharmaceutical compositions for local administration
|
EP1676569A1
(en)
*
|
2004-12-30 |
2006-07-05 |
Pevion Biotech Ltd. |
Lyophilization of virosomes
|
US20120021042A1
(en)
*
|
2005-09-15 |
2012-01-26 |
Steffen Panzner |
Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances
|
EP1764089A1
(en)
*
|
2005-09-15 |
2007-03-21 |
Novosom AG |
Serum stable liposomes comprising amphoter II lipid mixtures
|
US20080088046A1
(en)
*
|
2006-10-13 |
2008-04-17 |
Steffen Panzner |
Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
|
WO2007031333A2
(en)
*
|
2005-09-15 |
2007-03-22 |
Novosom Ag |
Improvements in or relating to amphoteric liposomes
|
EP1911443A1
(en)
*
|
2006-10-13 |
2008-04-16 |
Novosom AG |
Amphoteric liposomes, method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
|
US8093369B2
(en)
*
|
2005-10-11 |
2012-01-10 |
Ben Gurion University Of The Negev Research And Development Authority Ltd. |
Compositions for silencing the expression of VDAC1 and uses thereof
|
EP1971371B1
(en)
|
2005-12-01 |
2015-08-05 |
Pronai Therapeutics, Inc. |
Cancer therapies and pharmaceutical compositions used therein
|
US8367628B2
(en)
|
2005-12-01 |
2013-02-05 |
Pronai Therapeutics, Inc. |
Amphoteric liposome formulation
|
EP3067047B1
(en)
|
2005-12-08 |
2022-04-20 |
Insmed Incorporated |
Lipid-based compositions of antiinfectives for treating pulmonary infections
|
US20080089927A1
(en)
*
|
2006-04-06 |
2008-04-17 |
Vladimir Malinin |
Methods for Coacervation Induced Liposomal Encapsulation and Formulations Thereof
|
WO2008043575A2
(en)
*
|
2006-10-13 |
2008-04-17 |
Novosom Ag |
Improvements in or relating to amphoteric liposomes
|
US20140178462A1
(en)
*
|
2006-10-13 |
2014-06-26 |
Marina Biotech, Inc. |
Amphoteric liposomes comprising neutral lipids
|
JP2010513354A
(en)
*
|
2006-12-19 |
2010-04-30 |
ノヴォソム アクチェンゲゼルシャフト |
Lipids and lipid aggregates containing transfection enhancer elements
|
EP2308514B1
(en)
|
2007-03-23 |
2013-06-05 |
to-BBB Holding B.V. |
Conjugates for targeted drug delivery across the blood-brain barrier
|
CA2629387A1
(en)
*
|
2007-04-17 |
2008-10-17 |
Drew A. Vermeire |
Milk replacer composition and product and method for producing the same
|
JP5475643B2
(en)
|
2007-05-04 |
2014-04-16 |
マリーナ バイオテック,インコーポレイテッド |
Amino acid lipids and uses thereof
|
WO2008137717A1
(en)
|
2007-05-04 |
2008-11-13 |
Transave, Inc. |
Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
|
US9119783B2
(en)
|
2007-05-07 |
2015-09-01 |
Insmed Incorporated |
Method of treating pulmonary disorders with liposomal amikacin formulations
|
US9114081B2
(en)
|
2007-05-07 |
2015-08-25 |
Insmed Incorporated |
Methods of treating pulmonary disorders with liposomal amikacin formulations
|
US8822409B2
(en)
|
2007-06-20 |
2014-09-02 |
Phylogica Limited |
Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith
|
DE102007029471A1
(en)
|
2007-06-20 |
2008-12-24 |
Novosom Ag |
New optional cationic sterols
|
CA2699671C
(en)
*
|
2007-09-07 |
2015-07-14 |
Synvolux Ip B.V. |
Liposomes comprising amphiphiles with pyridinium head groups and uses thereof
|
CA2702103A1
(en)
*
|
2007-10-12 |
2009-04-16 |
Novosom Ag |
Improvements in or relating to amphotaric liposomes comprising neutral lipids
|
CN102112110A
(en)
*
|
2008-06-06 |
2011-06-29 |
米尔纳医疗股份有限公司 |
Novel compositions for the in vivo delivery of RNAi agents
|
CN104382853A
(en)
|
2008-10-16 |
2015-03-04 |
玛瑞纳生物技术有限公司 |
Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics
|
EP2414519A1
(en)
*
|
2009-03-31 |
2012-02-08 |
Council of Scientific & Industrial Research |
Amphoteric liposomal compositions for cellular delivery of small rna molecules for use in rna interference
|
JP5392707B2
(en)
*
|
2009-03-31 |
2014-01-22 |
株式会社Nttドコモ |
Membrane vesicle division system
|
WO2010135714A2
(en)
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Methods for modulating adipocyte expression using microrna compositions
|
WO2011003834A1
(en)
*
|
2009-07-09 |
2011-01-13 |
Marina Biotech, Inc. |
Amphoteric liposomes comprising imino lipids
|
ATE554749T1
(en)
*
|
2009-07-09 |
2012-05-15 |
Marina Biotech Inc |
IMITATION OF LIPOPROTEIN STRUCTURES
|
NZ600616A
(en)
|
2009-12-01 |
2014-11-28 |
Shire Human Genetic Therapies |
Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
|
WO2011120023A1
(en)
|
2010-03-26 |
2011-09-29 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting survivin gene expression uses thereof
|
WO2011133584A2
(en)
|
2010-04-19 |
2011-10-27 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting hras gene expression and uses thereof
|
WO2011139842A2
(en)
|
2010-04-28 |
2011-11-10 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
CA2813466A1
(en)
|
2010-10-01 |
2012-04-05 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids that disrupt major groove binding partner interactions
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
US9880151B2
(en)
|
2011-05-23 |
2018-01-30 |
Phylogica Limited |
Method of determining, identifying or isolating cell-penetrating peptides
|
EP4043025A1
(en)
|
2011-06-08 |
2022-08-17 |
Translate Bio, Inc. |
Lipid nanoparticle compositions and methods for mrna delivery
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
CN110511939A
(en)
|
2011-10-03 |
2019-11-29 |
现代泰克斯公司 |
Nucleosides, nucleotide and nucleic acid of modification and application thereof
|
EP2791160B1
(en)
*
|
2011-12-16 |
2022-03-02 |
ModernaTX, Inc. |
Modified mrna compositions
|
CN102532259A
(en)
*
|
2012-03-09 |
2012-07-04 |
中国药科大学 |
Oligopeptide-based cationic lipid derivative and application thereof in pharmaceutical preparation
|
CN102603866B
(en)
*
|
2012-03-15 |
2014-01-15 |
中国药科大学 |
Oligopeptide-based pH-sensitive amphoteric ion and application thereof in medicament
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
EP2833923A4
(en)
|
2012-04-02 |
2016-02-24 |
Moderna Therapeutics Inc |
Modified polynucleotides for the production of proteins
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
KR102277921B1
(en)
|
2012-05-21 |
2021-07-14 |
인스메드 인코포레이티드 |
Systems for treating pulmonary infections
|
US20150267192A1
(en)
|
2012-06-08 |
2015-09-24 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
US9763881B2
(en)
*
|
2012-06-11 |
2017-09-19 |
Council Of Scientific And Industrial Research |
Rice bran-lipids based formulation and process for preparation thereof for selective delivery of genes to cancer cells
|
ES2912033T3
(en)
|
2012-10-23 |
2022-05-24 |
Caris Science Inc |
Aptamers and uses thereof
|
US10942184B2
(en)
|
2012-10-23 |
2021-03-09 |
Caris Science, Inc. |
Aptamers and uses thereof
|
KR20150087270A
(en)
|
2012-11-05 |
2015-07-29 |
프로나이 테라퓨틱스, 인코포레이티드 |
Methods of using biomarkers for the treatment of cancer by modulation of bcl2 expression
|
PT2922554T
(en)
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Terminally modified rna
|
AU2013352259B2
(en)
|
2012-11-29 |
2018-06-14 |
Insmed Incorporated |
Stabilized vancomycin formulations
|
US9939443B2
(en)
|
2012-12-19 |
2018-04-10 |
Caris Life Sciences Switzerland Holdings Gmbh |
Compositions and methods for aptamer screening
|
ES2708561T3
(en)
|
2013-03-14 |
2019-04-10 |
Translate Bio Inc |
Methods for the purification of messenger RNA
|
PE20151773A1
(en)
|
2013-03-14 |
2015-12-20 |
Shire Human Genetic Therapies |
CFTR mRNA COMPOSITIONS, METHODS AND RELATED USES
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
JP2016519076A
(en)
|
2013-03-15 |
2016-06-30 |
ミルナ セラピューティクス,インク. |
Combined treatment of cancer using microRNA and EGFR-TKI inhibitor
|
AU2014302702A1
(en)
|
2013-06-24 |
2015-12-17 |
Mirna Therapeutics, Inc. |
Biomarkers of miR-34 activity
|
JP5914418B2
(en)
|
2013-06-26 |
2016-05-11 |
富士フイルム株式会社 |
Lipid particle, nucleic acid delivery carrier, composition for producing nucleic acid delivery carrier, lipid particle production method and gene introduction method
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
SG11201602503TA
(en)
|
2013-10-03 |
2016-04-28 |
Moderna Therapeutics Inc |
Polynucleotides encoding low density lipoprotein receptor
|
EP4276176A3
(en)
|
2013-10-22 |
2024-01-10 |
Translate Bio, Inc. |
Mrna therapy for argininosuccinate synthetase deficiency
|
MX2016005239A
(en)
|
2013-10-22 |
2016-08-12 |
Shire Human Genetic Therapies |
Mrna therapy for phenylketonuria.
|
US20160136181A1
(en)
|
2014-04-01 |
2016-05-19 |
Mirna Therapeutics, Inc |
Microrna dosing regimens
|
EP3981437A1
(en)
|
2014-04-23 |
2022-04-13 |
ModernaTX, Inc. |
Nucleic acid vaccines
|
KR20220158867A
(en)
|
2014-04-25 |
2022-12-01 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Methods for purification of messenger rna
|
ES2820226T3
(en)
|
2014-05-15 |
2021-04-20 |
Insmed Inc |
Methods for treating nontuberculous mycobacterial lung infections
|
JP6240570B2
(en)
|
2014-07-17 |
2017-11-29 |
富士フイルム株式会社 |
Lipid particles and nucleic acid delivery carriers
|
WO2016125163A1
(en)
|
2015-02-04 |
2016-08-11 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
LIPID ASSEMBLIES AND USES THEREOF AND SOME pH AND ELECTROSTATIC MODULATING LIPIDS TO BE USED IN SAID ASSEMBLIES
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
PT3350157T
(en)
|
2015-09-17 |
2022-03-18 |
Modernatx Inc |
Compounds and compositions for intracellular delivery of therapeutic agents
|
ES2924407T3
(en)
|
2015-12-10 |
2022-10-06 |
Modernatx Inc |
Compositions and methods for the delivery of therapeutic agents
|
ES2913626T3
(en)
|
2015-12-22 |
2022-06-03 |
Modernatx Inc |
Compounds and compositions for the intracellular delivery of agents
|
WO2018089540A1
(en)
|
2016-11-08 |
2018-05-17 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
AU2018224326B2
(en)
|
2017-02-27 |
2024-01-04 |
Translate Bio, Inc. |
Novel codon-optimized CFTR mRNA
|
WO2018170322A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
ES2940259T3
(en)
|
2017-03-15 |
2023-05-04 |
Modernatx Inc |
Compound and compositions for intracellular delivery of therapeutic agents
|
US11173190B2
(en)
|
2017-05-16 |
2021-11-16 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
|
MA49421A
(en)
|
2017-06-15 |
2020-04-22 |
Modernatx Inc |
RNA FORMULATIONS
|
US11744801B2
(en)
|
2017-08-31 |
2023-09-05 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
KR20200050982A
(en)
*
|
2017-09-04 |
2020-05-12 |
이치마루 화루코스 가부시키가이샤 |
pH-sensitive liposomes and preparation method thereof
|
WO2019048645A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
Stabilized cebpa sarna compositions and methods of use
|
MX2020003413A
(en)
*
|
2017-10-20 |
2020-07-20 |
BioNTech SE |
Preparation and storage of liposomal rna formulations suitable for therapy.
|
WO2019118806A1
(en)
|
2017-12-14 |
2019-06-20 |
Solid Biosciences Inc. |
Non-viral production and delivery of genes
|
JP7460534B2
(en)
|
2018-03-30 |
2024-04-02 |
インスメッド インコーポレイテッド |
Continuous manufacturing method for liposome medicines
|
EP4242307A3
(en)
|
2018-04-12 |
2023-12-27 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
US20190381034A1
(en)
*
|
2018-06-14 |
2019-12-19 |
Ming Fang |
Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases
|
AU2019325702A1
(en)
|
2018-08-24 |
2021-02-25 |
Translate Bio, Inc. |
Methods for purification of messenger RNA
|
US20210292766A1
(en)
|
2018-08-29 |
2021-09-23 |
University Of Massachusetts |
Inhibition of Protein Kinases to Treat Friedreich Ataxia
|
WO2020208361A1
(en)
|
2019-04-12 |
2020-10-15 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
CN114728887A
(en)
|
2019-09-19 |
2022-07-08 |
摩登纳特斯有限公司 |
Branched tail end lipid compounds and compositions for intracellular delivery of therapeutic agents
|
WO2021255262A1
(en)
|
2020-06-19 |
2021-12-23 |
Sylentis Sau |
siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
EP4015634A1
(en)
|
2020-12-15 |
2022-06-22 |
Sylentis, S.A.U. |
Sirna and compositions for prophylactic and therapeutic treatment of virus diseases
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
KR20230160872A
(en)
|
2021-03-26 |
2023-11-24 |
미나 테라퓨틱스 리미티드 |
TMEM173 SARNA composition and methods of use
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|